Clinical trials indicate that dual GLP-1/GIP co-agonists, such as tirzepatide, should be considered the most effective agents compared to other antihyperglycemic drugs in the early stage as well as long-lasting T2D [199,200,201,202,203,204]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.